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UPN18 UPN 26 UPN 45
CML phase pre-BMT II CP ICP I CP
Donor/recipient sex F/F MIM M/F
Conditioning regiment BU16+Vp30+Cy120 Bu16+Vp30+Cy120 Bu16+Cy120
tor BMT
GvHD praphylaxis Csa + MTX Csa + MTX Csa + MTX
GvHD occurrences after Not observed Not observed II o (skin)
BMT
Relapse after BMT +76 m-c +52 m-c +23 m-c
Hematological - AP Hematological - AP Hematological - CP
Relapse therapy prior DLI HU HU + INF-a. HU
DLI I 1,0 x 108 I 3,0 X 107 I 0,5 X 108
(donor CD3 dose/kg II 1,0 x 108 II 0,5 x 108
III 1,0 x 108
INF-a. after DLI (+) (+) (+)
Evaluation ot efficacy and moditication ot the treatment have been based on results ot FISH
tor Philadelphia chromosome detection and cellular chimerism in case ot sex-mismatch.
Results: UPN18 UPN 26 UPN 45
GvHD not observed not observed not observed
Pancytopenia observed not observed observed
Time trom 1st DLI - + 162 +618
to cytogenetic remision
Disease status at last Hematol. remission Hematol. remission Hematol. remission
tollow up (10%) Ph+ (FI8H) (10%) Ph+ (FI8H) (7%) Ph+ (FI8H)
tram day +665 trom day +532 tram day +1108
22 months 17,7 months 37 months
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The aim ot this study was to compare
results ot MRD and hematopoietie
ehimerism obtained by several moleeular
methods (FISH, RT-PCR, STR-PCR)
in children with post-transplant CML
relapse treated with adoptive immuno-
therapy. Genomie DNA was isolated trom
trozen whole peripheral blood by salting-
out method, amplitied with tluorescent
polymerase ehain reaetion primers
(speeitie tor 8TR marker loei: FGA, VWA,
TH01, F13A1, D21 811) and analysed
using quantitative automated DNA sizing
technology. FISH was carried out on inter-
phase nuclei with the use ot probes
speeitie tor X and Y-chromosomes (DXZ 1
and DYZ 1 loei). Results obtained with
the use ot FISH, RT-PCR and STR-PCR
were shown in table.
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Patient A.S. (UPN 26) Patient M.L. (UPN 45) Patient E.M. (UPN 18)
A1Io-BMT - 8.11.1994 Allo-BMT -15.11.1996 Allo-BMT - 24.08.1993
CML FISH RT- Chimerism* CML FISH RT- Chimeris FISH CML FISH RT- Chimeris




16.03.99 50% Recipient's 20.10.98 60-80% R 08.02.00 9,9% Mixed
genotype
12-24.03.99 21.10.98 29.02.00 23,1% Recipient's
HU OLiI genotype
24.03.99 HU lOll Mixed
-11.01.00 7.10-5.11.98 14.03.00
INF-alfa
28.10.99 2,92% b3a2 100%0 INF-alfa 12.04.00 37,3% b3a Mixed
02.11.- 2
02.12.98
04.11.99 b3a2 18.01.99 b2a2 60-80 % R 26.04.00 51,3%
16.02.00 2% 01.03.99 b2a2 20-40 % R II OLi
05.05.00
14.06.00 100%0 23.03.99 b2a2 10-20 % R 06.06.00 2,2% b3a Mixed
2
27.06.00 100%0 29.03.99 2% b2a2 100%0 04.07.00 b3a 100%0
2b2
a2




lOLl 100%0 05.07.99 17% b2a2 100%0 14.11.00 b2a 100%0
28.06.00 2
30.08.00 3% 100%0 22.09.99 6% b2a2 100%0 8% XX 10.01.01 b3a
2b2
a2
07.12.00 0% b2a2 100 % 0 28.09.99 b2a2 07.02.01 b3a
2
25.04.01 22% b2a2 22.12.99 5% b2a2 09.04.01
26.06.01 10% b2a2 29.03.00 1,97% b2a2 100%0 27.06.01 100% 0
28.08.01 21% b2a2 100%0 06.06.00 b2a2 100%0
29.09.01 10% b2a2 06.09.00 0% - 100%0 100%
XV




22.03.01 0% b2a2 100 % 0 100%
XV
12.09.01 7% b2a2 100 %0
09.11.01 23% b2a2 100%0 77%
XV
* examinations of chimerism status with
the use of STR-PCR were performed
without recipient's control sample before
BMT.
Conclusion: Combined evaluation
of the minimal residual disease by FISH,
RT-PCR and hematopoietic chimerism
by STR-PCR method gives more
informative details concerning response
to adoptive immunotherapy in post-
transplant relapsed CML patients with
BCR/ABL fusion gene.
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